1. Home
  2. PHAR vs EZPW Comparison

PHAR vs EZPW Comparison

Compare PHAR & EZPW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAR
  • EZPW
  • Stock Information
  • Founded
  • PHAR 1988
  • EZPW 1989
  • Country
  • PHAR Netherlands
  • EZPW United States
  • Employees
  • PHAR N/A
  • EZPW N/A
  • Industry
  • PHAR Biotechnology: Pharmaceutical Preparations
  • EZPW Other Specialty Stores
  • Sector
  • PHAR Health Care
  • EZPW Consumer Discretionary
  • Exchange
  • PHAR Nasdaq
  • EZPW Nasdaq
  • Market Cap
  • PHAR 798.2M
  • EZPW 814.0M
  • IPO Year
  • PHAR N/A
  • EZPW 1991
  • Fundamental
  • Price
  • PHAR $13.70
  • EZPW $16.00
  • Analyst Decision
  • PHAR Strong Buy
  • EZPW Strong Buy
  • Analyst Count
  • PHAR 3
  • EZPW 3
  • Target Price
  • PHAR $30.00
  • EZPW $19.33
  • AVG Volume (30 Days)
  • PHAR 12.8K
  • EZPW 801.7K
  • Earning Date
  • PHAR 07-31-2025
  • EZPW 07-30-2025
  • Dividend Yield
  • PHAR N/A
  • EZPW N/A
  • EPS Growth
  • PHAR N/A
  • EZPW 23.23
  • EPS
  • PHAR N/A
  • EZPW 1.29
  • Revenue
  • PHAR $339,836,000.00
  • EZPW $1,232,018,000.00
  • Revenue This Year
  • PHAR $12.88
  • EZPW $9.93
  • Revenue Next Year
  • PHAR $8.54
  • EZPW $6.42
  • P/E Ratio
  • PHAR N/A
  • EZPW $12.44
  • Revenue Growth
  • PHAR 22.44
  • EZPW 8.31
  • 52 Week Low
  • PHAR $6.73
  • EZPW $10.56
  • 52 Week High
  • PHAR $17.08
  • EZPW $16.60
  • Technical
  • Relative Strength Index (RSI)
  • PHAR 67.43
  • EZPW 66.36
  • Support Level
  • PHAR $12.13
  • EZPW $15.42
  • Resistance Level
  • PHAR $12.76
  • EZPW $16.34
  • Average True Range (ATR)
  • PHAR 0.89
  • EZPW 0.35
  • MACD
  • PHAR 0.13
  • EZPW 0.03
  • Stochastic Oscillator
  • PHAR 44.41
  • EZPW 81.01

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About EZPW EZCORP Inc. Non Voting

EZCORP Inc is a United States-based company engaged in offering pawn loans in the United States and Mexico. It also offers short-term unsecured loans and other consumer financial products, and buy and sell second-hand goods. The operating segments of the company are us Pawn, Latin America Pawn, and other international. us Pawn segment includes all pawn activities in the United States. Latin America Pawn segment includes all pawn activities in Mexico and other parts of Latin America. The company generates revenue from merchandise sales, jewelry scrapping sales, and pawn service charges, of which key revenue is derived from the merchandise sales which are primarily collateral forfeited from pawn lending operations and used merchandise purchased from the customers.

Share on Social Networks: